The Feasibility, Safety, and Early Response of Tisagenlecleucel Therapy for Pediatric Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

被引：0
|
作者：
Gocho, Yoshihiro [1 ]
Sakaguchi, Hirotoshi [1 ]
Iguchi, Akihiro [1 ]
Nishimura, Nao [2 ]
Uchiyama, Toru [3 ]
Deguchi, Takao [1 ]
Kato, Motohiro [1 ]
Tomizawa, Daisuke [1 ]
Onodera, Masafumi [3 ]
Matsumoto, Kimikazu [1 ]
机构：
[1] Natl Ctr Child Hlth & Dev, Childrens Canc Ctr, Tokyo, Japan
[2] Natl Ctr Child Hlth & Dev, Dept Crit Care & Anesthesia, Tokyo, Japan
[3] Natl Ctr Child Hlth & Dev, Dept Human Genet, Tokyo, Japan
来源：
PEDIATRIC BLOOD & CANCER | 2021年 / 68卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OS1-16
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Tisagenlecleucel for treatment of children and young adults with relapsed/refractory B-cell acute lymphoblastic leukemia
    Si Lim, Stephanie J.
    Grupp, Stephen A.
    DiNofia, Amanda M.
    PEDIATRIC BLOOD & CANCER, 2021, 68 (09)
  • [2] Efficacy and safety of tisagenlecleucel in Japanese pediatric and young adult patients with relapsed/refractory B cell acute lymphoblastic leukemia
    Hidefumi Hiramatsu
    Souichi Adachi
    Katsutsugu Umeda
    Itaru Kato
    Lamis Eldjerou
    Andrea Chassot Agostinho
    Kazuto Natsume
    Kota Tokushige
    Yoko Watanabe
    Stephan A. Grupp
    International Journal of Hematology, 2020, 111 : 303 - 310
  • [3] Tisagenlecleucel immunogenicity in relapsed/refractory acute lymphoblastic leukemia and diffuse large B-cell lymphoma
    Mueller, Karen Thudium
    Grupp, Stephan A.
    Maude, Shannon L.
    Levine, John E.
    Pulsipher, Michael A.
    Boyer, Michael W.
    August, Keith J.
    Myers, G. Doug
    Tam, Constantine S.
    Jaeger, Ulrich
    Foley, Stephen Ronan
    Borchmann, Peter
    Schuster, Stephen J.
    Waller, Edmund K.
    Awasthi, Rakesh
    Potthoff, Bernd
    Warren, Andy
    Waldron, Edward R.
    McBlane, Fraser
    Chassot-Agostinho, Andrea
    Laetsch, Theodore W.
    BLOOD ADVANCES, 2021, 5 (23) : 4980 - 4991
  • [4] Efficacy and safety of tisagenlecleucel in Japanese pediatric and young adult patients with relapsed/refractory B cell acute lymphoblastic leukemia
    Hiramatsu, Hidefumi
    Adachi, Souichi
    Umeda, Katsutsugu
    Kato, Itaru
    Eldjerou, Lamis
    Agostinho, Andrea Chassot
    Natsume, Kazuto
    Tokushige, Kota
    Watanabe, Yoko
    Grupp, Stephan A.
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2020, 111 (02) : 303 - 310
  • [5] CTL019 (tisagenlecleucel): CAR-T therapy for relapsed and refractory B-cell acute lymphoblastic leukemia
    Vairy, Stephanie
    Garcia, Julia Lopes
    Teira, Pierre
    Bittencourt, Henrique
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2018, 12 : 3885 - 3898
  • [6] Blinatumomab in pediatric patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia
    Queudeville, Manon
    Schlegel, Patrick
    Heinz, Amadeus T.
    Lenz, Teresa
    Doering, Michaela
    Holzer, Ursula
    Hartmann, Ulrike
    Kreyenberg, Hermann
    von Stackelberg, Arend
    Schrappe, Martin
    Zugmaier, Gerhard
    Feuchtinger, Tobias
    Lang, Peter
    Handgretinger, Rupert
    Ebinger, Martin
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2021, 106 (04) : 473 - 483
  • [7] FDA Approval Summary: Tisagenlecleucel for Treatment of Patients with Relapsed or Refractory B-cell Precursor Acute Lymphoblastic Leukemia
    O'Leary, Maura C.
    Lu, Xiaobin
    Huang, Ying
    Lin, Xue
    Mahmood, Iftekhar
    Przepiorka, Donna
    Gavin, Denise
    Lee, Shiowjen
    Liu, Ke
    George, Bindu
    Bryan, Wilson
    Theoret, Marc R.
    Pazdur, Richard
    CLINICAL CANCER RESEARCH, 2019, 25 (04) : 1142 - 1146
  • [8] Indirect comparison of tisagenlecleucel and blinatumomab in pediatric relapsed/refractory acute lymphoblastic leukemia
    Verneris, Michael R.
    Ma, Qiufei
    Zhang, Jie
    Keating, Amy
    Tiwari, Ranjan
    Li, Junlong
    Yang, Hongbo
    Agarwal, Abhijit
    Pacaud, Lida
    BLOOD ADVANCES, 2021, 5 (23) : 5387 - 5395
  • [9] Tisagenlecleucel for the treatment of B-cell acute lymphoblastic leukemia
    Leahy, Allison Barz
    Elgarten, Caitlin W.
    Grupp, Stephan A.
    Maude, Shannon L.
    Teachey, David T.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2018, 18 (10) : 959 - 971
  • [10] Molecular response with blinatumomab in relapsed/refractory B-cell precursor acute lymphoblastic leukemia
    Goekbuget, Nicola
    Kantarjian, Hagop M.
    Brueggemann, Monika
    Stein, Anthony S.
    Bargou, Ralf C.
    Dombret, Herve
    Fielding, Adele K.
    Heffner, Leonard
    Rigal-Huguet, Francoise
    Litzow, Mark
    O'Brien, Susan
    Zugmaier, Gerhard
    Gao, Shan
    Nagorsen, Dirk
    Forman, Stephen J.
    Topp, Max S.
    BLOOD ADVANCES, 2019, 3 (20) : 3033 - 3037
12345